Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-5. (Cancelled).

6. (Currently Amended) An adhesive preparation for percutaneous absorption consisting essentially of~~:~~ a base polymer, norethisterone, estradiol, a softener, and an adhesive resin, wherein

the base polymer consists essentially of ~~for the adhesive preparation which~~ contains ~~a~~ styrene-isoprene-styrene block copolymer;

~~an amount of~~the norethisterone is dissolved in the adhesive preparation ~~dissolved in the base preparation~~ without crystallization in the absence of hexylene glycol;

the estradiol ~~in an amount~~ is not more than 2 % by weight based on the ~~whole base~~adhesive preparation;

~~a~~ the softener is selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil; and

~~an~~ the adhesive resin is selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester.

7. (Previously Presented) The adhesive preparation for percutaneous absorption according to claim 6, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP ~~Dug~~-Drug release Test under the following conditions:

Test solution	900 ml water;
Temperature of test solution	32.0 ± 0.5°C;
Distance from the lowest end of cylinder to the basal inner plane of vessel	25 ± 2 mm; and
Revolution of cylinder	50 rpm.

8. (Currently Amended) An adhesive preparation for percutaneous absorption consisting essentially of~~:~~ a base polymer, norethisterone, estradiol, a polyisobutylene solubilizing agent, a softener, and an adhesive resin, wherein

the base polymer consists essentially of ~~for the adhesive preparation which contains~~ a styrene-isoprene-styrene block copolymer;

~~an amount of~~the norethisterone is dissolved in the adhesive preparation ~~dissolved in the base preparation~~ without crystallization in the absence of hexylene glycol;

the estradiol in ~~an amount~~ not more than 2 % by weight based on the adhesive preparation~~whole base~~;

~~a~~ the softener is selected from liquid paraffin, polybutene, castor oil, cottonseed oil, palm oil, coconut oil, and processed oil; and

~~an~~ the adhesive resin is selected from alicyclic saturated hydrocarbon resins, rosin ester, hydrogen alicyclic hydrocarbon, terpene-based hydrogenated resin, and hydrogenated rosin ester~~; and~~

~~a polyisobutylene solubilizing agent~~.

9. (Previously Presented) The adhesive preparation for percutaneous absorption according to claim 8, wherein norethisterone is dissolved in the amount showing the releasing rate in water being not less than 30% after 25 hours determined by the drug releasing test according to the cylinder method described in the USP ~~Dug~~ Drug release Test under the following conditions:

Test solution	900 ml water;
Temperature of test solution	32.0 ± 0.5°C;
Distance from the lowest end of cylinder to the basal inner plane of vessel	25 ± 2 mm; and
Revolution of cylinder	50 rpm.

10. (Previously Presented) The adhesive preparation for percutaneous absorption according to any of claims 6 – 9, wherein an amount of norethisterone to be dissolved is in the amount not more than 2 % by weight based on the whole base.

11. (Previously Presented) The adhesive preparation for percutaneous absorption according to any of claims 6 - 9, wherein the adhesive preparation containing a styrene-isoprene-styrene block copolymer comprises 10 – 30 % by weight of a styrene-isoprene-styrene block copolymer, 10 – 60 % by weight of a softener and 20 – 60 % by weight of an adhesive resin based on the whole base.

12. (New) The adhesive preparation for percutaneous absorption according to any one of claims 6 – 9, wherein the adhesive preparation further consists of an antioxidant.

13. (New) The adhesive preparation for percutaneous absorption according to claim 12, wherein the antioxidant is dibutylhydroxytoluene.